# OnCo record cobimetinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cobimetinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cobimetinib" ;
  schema:name "Cobimetinib"@en ;
  schema:description "Cobimetinib is the MEK partner for vemurafenib, and the first drug approved for histiocytic neoplasms."@en ;
  schema:url <https://onco.cc/drugs/cobimetinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cobimetinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q15708292> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cobimetinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (MEK1/2)" ;
  schema:alternateName "Cotellic" ;
  onco:approval "US 2015: BRAF V600 melanoma with vemurafenib", "US 2020: With atezolizumab and vemurafenib in BRAF V600 melanoma", "US 2022: Histiocytic neoplasms" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/erdheim-chester-disease/>, <https://onco.cc/cancers/rosai-dorfman-disease/>, <https://onco.cc/cancers/lch-single-system/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/nct04302025/>, <https://onco.cc/trials/nct07449754/>, <https://onco.cc/trials/nct04931342/>, <https://onco.cc/trials/imblaze370/> .